Trial Profile
Efficacy of nivolumab and pembrolizumab monotherapy in patients with non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Feb 2017
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 03 Feb 2017 New trial record
- 07 Dec 2016 Results presented at the 17th World Conference on Lung Cancer